Antipsychotics trieved by calculating Number Needed to Treat (NNT) for prevention of depression and NNT for Index value above 1.0 indicates a relative greater antimanic prophylactic efficacy, number www.e l sev i e r. com / l European Neuropsychopharmacology (2012) 22, 339–346below 1.0 a relative greater antidepressive efficacy. The polarity index for the drugs used in maintenance therapy for bipolar disorder was 12.09 for risperidone, 4.38 for aripiprazole, 3.91 for ziprasidone, 2.98 for olanzapine, 1.39 for lithium, 1.14 for quetiapine, and 0.40 for lamotri-gine. Polarity index of valproate and oxcarbazepine may not be reliable due to the failure of their maintenance trials. The polarity index provides a measure of how much antidepressant...
BACKGROUND: Bipolar Disorder (BD) long-term treatment is aimed to prevent relapses associated with w...
Background: Bipolar disorder is a highly recurrent disease and has great impact on the function of p...
ABSTRACT FROM: Miura T, Noma H, Furukawa TA, et al. Comparative efficacy and tolerability of pharmac...
Objective: Predominant polarity (PP) is an important variable in maintenance treatment of Bipolar Di...
Background: Bipolar disorder (BD) is a serious and recurring condition that affects approximately 2....
Background: A large number of patients with bipolar disorder (BD) can be characterized by predominan...
<b><i>Background:</i></b> Although several adjunctive psychological interventions are effective in t...
Background and Objectives: Predominant polarity (PP) may be a useful course specifier in at least a ...
Bipolar disorder (BD) is a serious and recurring condition that affects approximately 2.4% of the gl...
AbstractThe medical community increasingly supports the use of simplifying constructs or ratios to f...
OBJECTIVES: This study compared 29 drugs for risk of psychiatric hospitalization in bipolar disorder...
Background Clinical trials have examined the efficacy of drugs to prevent relapse in patients with b...
Background and Objectives: Predominant polarity (PP) may be a useful course specifier in at least a ...
ABSTRACTBackgroundPredominant polarity (PP) is a proposed course specifier for bipolar disorder, whi...
Objective: The risk-benefit profile of antidepressant medications in bipolar disorder is controversi...
BACKGROUND: Bipolar Disorder (BD) long-term treatment is aimed to prevent relapses associated with w...
Background: Bipolar disorder is a highly recurrent disease and has great impact on the function of p...
ABSTRACT FROM: Miura T, Noma H, Furukawa TA, et al. Comparative efficacy and tolerability of pharmac...
Objective: Predominant polarity (PP) is an important variable in maintenance treatment of Bipolar Di...
Background: Bipolar disorder (BD) is a serious and recurring condition that affects approximately 2....
Background: A large number of patients with bipolar disorder (BD) can be characterized by predominan...
<b><i>Background:</i></b> Although several adjunctive psychological interventions are effective in t...
Background and Objectives: Predominant polarity (PP) may be a useful course specifier in at least a ...
Bipolar disorder (BD) is a serious and recurring condition that affects approximately 2.4% of the gl...
AbstractThe medical community increasingly supports the use of simplifying constructs or ratios to f...
OBJECTIVES: This study compared 29 drugs for risk of psychiatric hospitalization in bipolar disorder...
Background Clinical trials have examined the efficacy of drugs to prevent relapse in patients with b...
Background and Objectives: Predominant polarity (PP) may be a useful course specifier in at least a ...
ABSTRACTBackgroundPredominant polarity (PP) is a proposed course specifier for bipolar disorder, whi...
Objective: The risk-benefit profile of antidepressant medications in bipolar disorder is controversi...
BACKGROUND: Bipolar Disorder (BD) long-term treatment is aimed to prevent relapses associated with w...
Background: Bipolar disorder is a highly recurrent disease and has great impact on the function of p...
ABSTRACT FROM: Miura T, Noma H, Furukawa TA, et al. Comparative efficacy and tolerability of pharmac...